THE DIFFERENTIATED LIPID-LOWERING THERAPY IN WOMEN WITH CORONARY HEART DISEASE IN MENOPAUSE

The aim of the study: to assess the impact of differentiated lipid-lowering therapy on lipid metabolism, immune and inflammatory changes in women with stable angina in menopause. Materials and methods: examined 97 women with stable angina functional class II at menopause (average age 53,6±4,24 years) using instrumental methods (ECG, EKTG-60, Holter ECG monitoring, loading test, coronary angiography) and laboratory (determined by hormonal status, fibrinogen level and hsSRB, lipid profile and blood products LPO). Depending on the identified changes of lipid metabolism prescribed lipid-lowering drugs: atorvastatin, ciprofibrat, combination atorvastatin with antisklerol. Results: after a course of differentiated lipid-lowering therapy in all treatment groups achieved target levels of lipid metabolism. However, in patients receiving atorvastatin significantly decreased the concentration of LPO products (p=0,039) and large molecular 3,5% immune complexes (IC), p=0,041 in early postmenopausal women, of low-molecular 7% IC (p=0,014) in the perimenopause, as well as decreased levels of antibodies to LDL in the late postmenopausal (p<0,01), indicating that the antioxidant and immunomodulatory activity of statins and suggests its function during exacerbation of atherosclerosis in menopausal women. Ciprofibrat treatment led to a reduction of

ИБС, стабильная стенокардия, менопауза, дислипидемия, гиполипидемическая терапия, CHD, stable angina, menopause, dyslipidemia, lipid-lowering therapy

1. Сметник В. П. Системные изменения у женщин в климактерии // Русский медицинский журнал -2001. -Т. 9, №9 (128). - С. 354-358.

2. Балан В. Е., Зайдиева Я. 3. Применение фитоэстрогенов для лечения гипоэстрогенных состояний // Русский медицинский журнал -2000. -Т. 8, №3. -С.56-61.

3. Helmersson J., Mattson P., Basu S., Prostaglandin F (2 alpha) metabolite and F2-isoprostane excretion in migraine //Clin. Sci. (Lond.). -2002. - 102. - P. 39-43.

4. Chen L. D., Kushawaha R. S., Mc'Gill H. Jr. et al. Effect of naturally reduced ovarian function on plasma lipoprotein and 27-hydroxycholrsterol levels in baboons (Papio sp.) // Aterosclerosis.-l998-136(l).-p. 89-98.

5. Ericsson C.G., Hamsten A., Nilsson J.et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male infarction patients//Lancet.-1996.-№ 347.-P. 849-853.

6. Goldbourt U., Brunner D., Behar S. et al. Baseline characteristics of patients participating in the Bezafibrate Infarction prevention (BIP) Study // Eur. Heart J.-1998.-№ 19.-Suppl. H:H42-H47.

7. Титов B.H. Патогенез атеросклероза для XXI века//Клин. лаб. диагностика.-1998-№ 1.-С 3-11.

8. Zucker М., Bilyeu D., Helkamp G. et al. Effects of dietary fish oil on platelet function and plasma lipids in hyper lipoproteinemic and normal subjects // Atherosclerosis.- 1995.-Vol.73.-№ l.-P. 13-27.

9. Leaf A., Weber P.C. Cardiovascular effects ofn-3 fatty acids. //N.Engl. J. Med.-1988.-318(9).-549-57.

10. Дюкова Г. М. Качество жизни женщины в период климактерии // Лечащий врач, 2003. - № 1. - С. 48-50.